Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

被引：0
|
作者：
Janne B Kjersem
Tone Ikdahl
Tormod Guren
Eva Skovlund
Halfdan Sorbye
Julian Hamfjord
Per Pfeiffer
Bengt Glimelius
Christian Kersten
Hiroko Solvang
Kjell M Tveit
Elin H Kure
机构：
[1] Institute for Cancer Research,Department of Genetics
[2] Oslo University Hospital,Department of Oncology
[3] Oslo University Hospital,School of Pharmacy
[4] University of Oslo and the Norwegian Institute of Public Health,Department of Oncology
[5] Haukeland University Hospital,Department of Oncology
[6] Odense University Hospital,Department of Radiology, Oncology and Radiation Science
[7] Uppsala University,Department of Oncology and Pathology
[8] Karolinska Institutet,Center for Cancer Treatment
[9] Southern Hospital Trust,undefined
来源：
BMC Cancer | / 12卷
关键词：
Colorectal cancer; LCS6; MiRNA polymorphism; Cetuximab; Oxaliplatin; 5-fluorouracil;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 37 条
  • [21] Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin
    Ichikawa, Wataru
    Ooyama, Akio
    Toda, Etsuko
    Sugimoto, Yoshikazu
    Oka, Toshinori
    Takahashi, Takehiro
    Shimizu, Michio
    Sasaki, Yasutsuna
    Hirayama, Renzo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (06) : 794 - 801
  • [22] Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
    Leonie JM Mekenkamp
    Jolien Tol
    Jeroen R Dijkstra
    Inge de Krijger
    M Elisa Vink-Börger
    Shannon van Vliet
    Steven Teerenstra
    Eveline Kamping
    Eugène Verwiel
    Miriam Koopman
    Gerrit A Meijer
    J Han JM van Krieken
    Roland Kuiper
    Cornelis JA Punt
    Iris D Nagtegaal
    BMC Cancer, 12
  • [23] Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
    L Paré
    E Marcuello
    A Altés
    E del Río
    L Sedano
    J Salazar
    A Cortés
    A Barnadas
    M Baiget
    British Journal of Cancer, 2008, 99 : 1050 - 1055
  • [24] Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
    Pare, L.
    Marcuello, E.
    Altes, A.
    del Rio, E.
    Sedano, L.
    Salazar, J.
    Cortes, A.
    Barnadas, A.
    Baiget, M.
    BRITISH JOURNAL OF CANCER, 2008, 99 (07) : 1050 - 1055
  • [25] Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil
    Han, Jae Joon
    Baek, Sun Kyung
    Lee, Jae Jin
    Kim, Gou Young
    Kim, Si-Young
    Lee, Suk-Hwan
    CANCER RESEARCH AND TREATMENT, 2014, 46 (01): : 55 - 64
  • [26] 3′-Deoxy-3′-18F-Fluorothymitline PET for the Early Prediction of Response to Leucovorin, 5-Fluorouracil, and Oxaliplatin Therapy in Patients with Metastatic Colorectal Cancer
    Hong, Yong Sang
    Kim, Hye Ok
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Kim, Hwa Jung
    Lee, Seung Jin
    Lee, Sang Ju
    Oh, Seung Jun
    Kim, Jae Seung
    Ryu, Jin-Sook
    Moon, Dae Hyuk
    Kim, Tae Won
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (08) : 1209 - 1216
  • [27] Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab plus Irinotecan
    Bando, Hideaki
    Yoshino, Takayuki
    Yuki, Satoshi
    Shinozaki, Eiji
    Nishina, Tomohiro
    Kadowaki, Shigenori
    Yamazaki, Kentaro
    Kajiura, Shinya
    Tsuchihara, Katsuya
    Fujii, Satoshi
    Yamanaka, Takeharu
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (12) : 1146 - 1151
  • [28] Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
    Kotake, Masanori
    Aoyama, Toru
    Munemoto, Yoshinori
    Doden, Kenji
    Kataoka, Masato
    Kobayashi, Kenji
    Nishimura, Genichi
    Fujita, Hidehito
    Nakamura, Keishi
    Takehara, Akira
    Tanaka, Chihiro
    Sakamot, Junichi
    NagatA', Naoki
    Oba, Koji
    Kondo, Ken
    ONCOLOGY LETTERS, 2017, 13 (02) : 747 - 753
  • [29] The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil
    Ben Fredj, R.
    Gross, E.
    Ben Ahmed, S.
    Hassine, H.
    Saguem, S.
    PATHOLOGIE BIOLOGIE, 2009, 57 (06): : 470 - 476
  • [30] Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
    Hiroshi Soeda
    Hideki Shimodaira
    Mika Watanabe
    Takao Suzuki
    Makio Gamoh
    Takahiro Mori
    Keigo Komine
    Noriyuki Iwama
    Shunsuke Kato
    Chikashi Ishioka
    International Journal of Clinical Oncology, 2013, 18 : 670 - 677
1234